From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Advanced Oncotherapy – Is It Placing Ahoy Amid Further Delay To Light System?

By Nigel Somerville, the Deputy Sheriff of AIM | Sunday 20 February 2022


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


I see that shares in AIM-listed Advanced Oncotherapy (AVO) are down to just 26.5p – only a penny and a half above the nominal price. Normally that might not be an issue, but Advanced is a serial non-deliverer of promises and has had to place at regular intervals until now. So what chance a bucket-shop placing to keep the lights on whilst we await the ever-delayed first LIGHT system to even offer a sprinkling of hope for some revenue?

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

CTAI

Catenai – monster dilution

Time left: 03:42:53